A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)

Next Previous
Trial Profile

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Apr 2018

At a glance

  • Drugs Belimumab (Primary) ; Rituximab
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Acronyms BLISS-BELIEVE
  • Sponsors GlaxoSmithKline

    • Most Recent Events

    • 10 Apr 2018 Planned End Date changed from 2 Jun 2021 to 9 Jun 2021.
    • 10 Apr 2018 Planned primary completion date changed from 27 Aug 2020 to 11 Jun 2020.
    • 05 Mar 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top